Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: MONOGRAPH

Risperidone

Plain-language summaryIntrigue 65 / 100

Risperidone (Risperdal) is the most prescribed atypical antipsychotic in the world. Janssen brought it to market in 1993 as the prototype of the combined dopamine D2 plus serotonin 5-HT2A blocker design that defined second-generation antipsychotics. Approved for schizophrenia, bipolar mania, and irritability in autism, it is also widely used off-label in dementia behavioral disturbance and various pediatric conditions. At low doses (1 to 2 mg) it acts more like a typical atypical; at higher doses (above 6 mg) the 5-HT2A advantage washes out and it produces extrapyramidal symptoms and prolactin elevation comparable to older haloperidol. Its active leftover is itself sold separately as paliperidone (Invega). Available as a long-acting injection (Risperdal Consta) for adherence support. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

47/100

The canonical D2/5-HT2A reference atypical: indispensable as a probe, not interesting as a discovery target

Look, risperidone is one of those compounds where the score almost writes itself. Approved in 1993, the most prescribed atypical antipsychotic on the planet, a metabolite (paliperidone) that got its own branded approval. The D2/5-HT2A dual antagonism profile was genuinely interesting when Janssen published it, but that was over thirty years ago, and the pharmacology has been beaten to death across thousands of studies. There is no open mechanism question here.

The receptor profile is textbook at this point: D2 at roughly 4 nM Ki, 5-HT2A at roughly 0.16 nM, a 25:1 ratio that drives the atypical character at low doses and collapses into something approaching haloperidol above 6 mg. The dose-EPS relationship is cited in every antipsychotic pharmacology lecture. The active metabolite contribution is fully characterized. The long-acting injectable formulations are mature commercial products. We’re not going to learn something new about risperidone by running another preclinical series on it.

Where it does hold up as a library entry is bench utility. If your lab is interrogating dopamine receptor biology, autism rodent models, antipsychotic-induced metabolic side effects, or the 5-HT2A / D2 interaction in prefrontal circuits, risperidone is the reference compound. Its well-characterized receptor kinetics and extensive pharmacokinetic database make it a reliable anchor for comparison studies. That’s not nothing. The bench value here is real, its just the value of a well-understood reference, not the value of a frontier probe.

Whats genuinely low here is novelty and mechanism promise. The combined D2/5-HT2A antagonist class is completely saturated. Aripiprazole took the partial agonist angle. Clozapine remains the efficacy benchmark with its messy multireceptor profile. Brexpiprazole and cariprazine refined the partial agonist story further. Risperidone sits as the prototype definition of the class, which means investigators in the field use it as a comparator, not an object of investigation. If you’re designing an experiment to answer a novel question about psychosis biology, risperidone is your control arm, not your experimental arm.

The evidence quality and translational scores are legitimately high. Three approved indications, multiple phase 3 programs, long-acting formulations with their own trial bases, decades of post-marketing surveillance. We’re not questioning the clinical reality. But the rubric asks whether a bench scientist should find this compound worth primary research time right now, and the honest answer is almost certainly no unless the goal is characterizing something new against a reliable reference. As a discovery target in 2025, risperidone is basically done.

Novelty

18

Mechanism promise

28

In-category differentiation

40

Evidence quality

82

Translational signal

75

Research bench value

65

Rationale Risperidone is a 1993-approved, fully characterized reference compound whose novelty and mechanism scores are floor-bound by three decades of settled pharmacology; evidence and translational scores are ceiling-bound by its FDA approval across three indications, but those high downstream scores can’t rescue the overall because the rubric weights novelty and mechanism heavily. Bench value is real but narrow: it scores meaningfully as a canonical probe for D2/5-HT2A biology, not as a frontier research target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Atypical antipsychotic

A benzisoxazole atypical antipsychotic; the most prescribed atypical worldwide and the prototype combined D2 / 5-HT2A antagonist.

Abstract

Risperidone (3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; CAS 106266-06-2; molecular formula C23H27FN4O2; molecular weight 410.49) is a benzisoxazole atypical antipsychotic developed at Janssen and approved by the FDA in 1993 under the trade name Risperdal. The receptor profile is the prototype combined D2/5-HT2A antagonist: D2 (Ki approximately 4 nM), 5-HT2A (Ki approximately 0.16 nM, ratio approximately 25:1 favoring 5-HT2A), with secondary alpha-1, alpha-2, and H1 antagonism. At doses below 6 mg the 5-HT2A predominates and EPS is minimal; above 6 mg the D2 antagonism produces dose-dependent EPS approaching haloperidol-like profile. The active metabolite 9-hydroxyrisperidone (paliperidone, marketed as Invega) carries similar receptor profile and contributes substantially to steady-state activity. Risperidone is the most prescribed atypical antipsychotic worldwide. Plasma half-life is 3 hours for parent, 24 hours for paliperidone metabolite. Long-acting injectables (Risperdal Consta, Perseris) provide biweekly or monthly administration. Approved for schizophrenia, bipolar mania, autism-associated irritability. Used as the canonical D2/5-HT2A reference atypical.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-239Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Tofisopam

Plain-language summaryIntrigue 56 / 100

Tofisopam (Grandaxin) is an unusual benzodiazepine from EGIS in Hungary, registered in the 1960s. The chemistry is technically a benzodiazepine, but the substitution pattern (a 2,3-fused ring rather than the standard 1,4-fused ring of diazepam and lorazepam) means it does not bind the classic GABA-A benzodiazepine site at all. As a result it produces anxiolysis without sedation, muscle relaxation, cognitive impairment, or dependence. The actual mechanism is not fully worked out, with proposals including phosphodiesterase inhibition and dopaminergic modulation. Approved across Europe and parts of Asia for anxiety and autonomic dysfunction; never approved in the US. Genuinely interesting pharmacologically because it shows that the benzodiazepine scaffold can do more than activate GABA-A. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

51/100

A structurally distinct non-GABA-A anxiolytic with real probe value and an incompletely mapped mechanism worth investigating

Here’s the thing about tofisopam: it’s not a benzodiazepine in the way that word usually lands. Yes, the diazepine ring is there, but the nitrogen positions are at the 2,3 carbons rather than the 1,4 positions of diazepam or lorazepam, and that single structural difference eliminates binding at the classical benzodiazepine allosteric site on GABA-A receptors entirely. That means no sedation from GABA current potentiation, no muscle relaxation from that pathway, and by most accounts no physical dependence profile that mirrors classical benzos. EGIS Pharmaceuticals in Hungary developed it in the 1960s, and it’s been marketed as Grandaxin in Hungary, France, and several Asian markets for decades under indications that include anxiety, autonomic instability, and post-stress recovery. For a compound this old to still have an incompletely characterized mechanism is either a red flag or a research opportunity depending on how you look at it.

We lean toward opportunity, cautiously. The leading hypotheses for tofisopam’s activity include phosphodiesterase IV (PDE4) inhibition and some form of dopaminergic modulation, possibly both operating in parallel. PDE4 inhibition is not a trivial mechanism: roflumilast got approved for COPD on that axis, and the neuroimmune and cognitive implications of PDE4 in the CNS have attracted serious attention over the last decade. If tofisopam genuinely hits PDE4 with relevant potency in neural tissue, thats a more interesting story than it usually gets credit for. The dopaminergic angle is less characterized but could explain the reported antifatigue and mood-brightening effects that dont fit a pure anxiolytic profile. What we dont have is a clean pharmacological dissection confirming which target drives which effect at clinically relevant concentrations.

The evidence base is the main drag on the score. Tofisopam has human approval, which is real, but the supporting literature is heavily weighted toward Eastern European clinical work from the 1970s through the 1990s, published in journals that dont make modern replication standards easy to verify. There isnt a modern phase 2 or phase 3 RCT benchmarking it against placebo or active comparators with current methodology. The preclinical literature is sparse compared to what you’d want before building a research program around it.

Where tofisopam earns its keep is as a reference tool. If your lab is trying to understand what non-GABAergic, non-serotonergic anxiolysis looks like pharmacologically, it’s essentially the only 2,3-benzodiazepine with a usable human history and commercial availability. That niche is real but narrow. Honestly, it scores where it scores because it’s genuinely interesting as a probe without being important enough in any active research conversation to rank higher. Investigators in autonomic pharmacology or PDE4 neuroimmunology should know it exists.

Novelty

42

Mechanism promise

55

In-category differentiation

60

Evidence quality

40

Translational signal

48

Research bench value

60

Rationale Tofisopam’s 2,3-benzodiazepine scaffold genuinely sidesteps classical GABA-A activity, making it the reference probe for non-sedating, non-dependence-forming anxiolysis via a mechanism that still isn’t fully nailed down; the European approval provides a real human signal, but the evidence base is dominated by older Eastern European literature with limited modern replication, keeping differentiation and bench value from pulling the score higher.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

2,3-benzodiazepine atypical anxiolytic

A 2,3-benzodiazepine without classical GABA-A activity; a non-sedating anxiolytic marketed in Europe.

Abstract

Tofisopam (1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine; CAS 22345-47-7; molecular formula C22H26N2O4; molecular weight 382.46) is a 2,3-benzodiazepine developed at EGIS (Hungary) in the 1960s and approved in Hungary, France, and other European and Asian markets under the trade name Grandaxin. Distinct from the 1,4-benzodiazepine class (diazepam, lorazepam, etc.) by the position of the nitrogens in the diazepine ring: the 2,3 isomer does not bind the classical benzodiazepine site on GABA-A receptors and lacks the GABA-A-mediated sedation, anxiolysis, and dependence of conventional benzodiazepines. The mechanism is incompletely characterized; possibilities include phosphodiesterase IV inhibition and modulation of dopaminergic signaling. Plasma half-life is approximately 6 to 8 hours; metabolism is hepatic. Approved indications in markets where registered include anxiety disorders, autonomic instability, and post-stress recovery; off-label use in fatigue and reactive depression. Not approved in the US. Used as a reference 2,3-benzodiazepine.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-254Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Tamoxifen

Plain-language summaryIntrigue 70 / 100

Tamoxifen (Nolvadex) is the foundational antiestrogen, FDA-approved in 1977 and one of the most-prescribed cancer drugs ever made. It is a selective estrogen receptor modulator (SERM): a blocker in breast tissue (the basis for hormone-receptor-positive breast cancer treatment and prevention) and a partial activator in bone, liver, and uterus. The active metabolite endoxifen, generated by the liver enzyme CYP2D6, is roughly a hundred times more potent than the parent drug, so people with low CYP2D6 activity may respond poorly. Off-label, it is widely used as post-cycle therapy by anabolic steroid users to restore natural testosterone production. Side effects include hot flashes and a small increase in endometrial cancer risk. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Selective estrogen receptor modulator (triphenylethylene)

A triphenylethylene SERM; the foundational antiestrogen for ER-positive breast cancer and an off-label tool for SARM/AAS post-cycle therapy.

Abstract

Tamoxifen ((Z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine; CAS 10540-29-1; molecular formula C26H29NO; molecular weight 371.51) is a triphenylethylene SERM developed at ICI Pharmaceuticals (now AstraZeneca) and approved by the FDA in 1977 under the trade name Nolvadex. The compound is a tissue-selective estrogen receptor modulator: antagonist in breast tissue (the basis for breast cancer indications) and partial agonist in bone, liver, and uterus. The active metabolite endoxifen (4-hydroxy-N-desmethyltamoxifen) generated via CYP2D6 is approximately 100-fold more potent than tamoxifen at ER binding and contributes substantially to clinical activity; CYP2D6 polymorphism affects clinical response. Plasma half-life is approximately 5 to 7 days for parent compound. Approved indications include adjuvant treatment of ER-positive breast cancer (premenopausal and postmenopausal), metastatic breast cancer, and breast cancer prevention in high-risk patients. Off-label use in male hypogonadism, gynecomastia treatment, and post-cycle therapy following SARM or anabolic steroid use is common. Adverse events include endometrial cancer (rare), thromboembolism, and hot flashes. Used as the canonical SERM in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-271Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Human Chorionic Gonadotropin (HCG)

Glycoprotein hormone (LH analog; placental origin)

Human chorionic gonadotropin; a placental glycoprotein hormone that activates the LH receptor; used in IVF, hypogonadism, and HPG axis recovery.

Abstract

Human chorionic gonadotropin (hCG; CAS 9002-61-3; alpha subunit and unique beta subunit; total molecular weight approximately 36800 Da) is a placental glycoprotein hormone composed of an alpha subunit (shared with LH, FSH, and TSH) and a unique beta subunit. The compound is the principal hormone of pregnancy, produced by syncytiotrophoblasts of the implanting embryo and detected as the basis for pregnancy tests. Pharmacologically, hCG acts as an LH receptor agonist with a substantially longer half-life than endogenous LH (approximately 36 hours versus 30 minutes), making it useful as a pharmacological tool to stimulate Leydig cell testosterone production in males or to trigger ovulation in IVF protocols. Approved indications: male hypogonadotropic hypogonadism (testosterone restoration with preservation of fertility), cryptorchidism, and as ovulation trigger in IVF (single 5000 to 10000 IU injection). Off-label use in TRT users to restore testicular function or as part of post-cycle therapy after AAS or SARM use. Plasma half-life of urinary-derived (Pregnyl, Novarel) versus recombinant (Ovidrel) forms are similar; both work clinically. Used as the canonical LH receptor agonist in HPG axis research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-287Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Vinpocetine

Plain-language summaryIntrigue 50 / 100

Vinpocetine (Cavinton) is a synthetic alkaloid derived from vincamine in the lesser periwinkle plant, developed at Gedeon Richter in Hungary in the 1960s. Approved across Europe for cerebrovascular insufficiency and used as a nootropic in the US (sold as a supplement). It works through several mechanisms at once: cerebral vasodilation, weak phosphodiesterase 1 inhibition, neuronal sodium channel block, and modest antioxidant activity, with the combined effect of improving blood flow to the brain. Clinical evidence in cognitive impairment and stroke recovery is mixed and dominated by older Eastern European trials with weak methodology. The FDA flagged it in 2019 over concerns about miscarriage in pregnant users. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

32/100

A 1960s cerebrovascular workhorse with weak PDE1 inhibition that has been surpassed by more selective modern tools

Vinpocetine is one of those compounds that was genuinely interesting in 1975 and has been coasting on that reputation ever since. Developed at Gedeon Richter in Hungary as a synthetic derivative of vincamine, it got approval across Eastern Europe under the Cavinton trade name and built up a moderately sized clinical literature, mostly through the 1980s and 1990s. That history is real. The problem is that the research has barely moved since.

The mechanism is pluripotent in the way that usually signals we don’t really know what’s driving the effect. PDE1 inhibition is the most cited angle, and it’s not a bad one; PDE1B and PDE1C have legitimate neurological relevance, and the cyclic nucleotide signaling cascade downstream is genuinely interesting biology. But vinpocetine’s PDE1 affinity is weak relative to selective inhibitors that came later. The cerebrovascular vasodilation story is real but not mechanistically novel. The sodium channel block exists but is modest. What you end up with is a compound that does several things modestly well rather than one thing exceptionally.

Differentiation is where vinpocetine struggles most against modern alternatives. If you’re interested in PDE1 specifically, ITI-214 (now lenrispodun) is a selective, high-affinity PDE1 inhibitor with clean human pharmacology data and a phase 2 trial in heart failure. If you want cerebrovascular effects, the field has largely moved to better-characterized agents. Vinpocetine competes with neither, and its FDA story is awkward: the agency has questioned whether it legally qualifies as a dietary supplement given its pharmaceutical development history, which creates a real sourcing ambiguity for US-based research programs.

The evidence base is an honest moderate score. There’s a multi-decade literature, some small RCTs in European populations, and a Cochrane review that found evidence insufficient to support use in dementia. Not nothing. But a lot of the primary literature comes from Eastern European groups with methodological standards that dont hold up well against modern expectations, and independent replication from Western labs is sparse. The translational signal exists, it’s just not compelling by current standards.

We think vinpocetine still has marginal utility as a rough PDE1 inhibitor tool in preclinical CNS work, particularly when selectivity isn’t the priority and broad cerebrovascular modulation is the goal. Thats a narrow use case. For investigators seriously studying PDE1 biology, ITI-214 is the right probe. For cerebrovascular research, the compound landscape looks very different in 2025 than it did when Cavinton was approved. Vinpocetine is a historical artifact that still holds a slot in the library, but serious bench scientists should know what they’re not getting when they reach for it.

Novelty

20

Mechanism promise

32

In-category differentiation

28

Evidence quality

45

Translational signal

40

Research bench value

35

Rationale Developed in the 1960s with a multi-decade Eastern European clinical literature, vinpocetine’s pluripotent-but-weak mechanism and poor differentiation against selective modern PDE1 inhibitors keep novelty and differentiation scores low; evidence quality is moderate given the Cochrane-reviewed RCT base, but independent Western replication is sparse and effect sizes are modest throughout.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic vincamine derivative / cerebrovascular agent

A synthetic alkaloid derivative of vincamine from Vinca minor; a cerebrovascular agent and PDE1 inhibitor used as a nootropic.

Abstract

Vinpocetine ((3-alpha,16-alpha)-eburnamenine-14-carboxylic acid ethyl ester; CAS 42971-09-5; molecular formula C22H26N2O2; molecular weight 350.46) is a synthetic alkaloid derivative of vincamine from Vinca minor (lesser periwinkle), developed at Gedeon Richter (Hungary) in the 1960s and approved in many European countries as Cavinton for cerebrovascular insufficiency. Mechanism is multifactorial: cerebral vasodilation through smooth muscle relaxation, weak phosphodiesterase 1 (PDE1) inhibition, sodium channel block in neurons, and modest antioxidant activity. The combined effect produces improved cerebral blood flow and reduced ischemic neuronal injury in animal stroke models. Plasma half-life is approximately 1 to 2 hours; metabolism is hepatic via CYP2C9 and CYP3A4. Approved indications in Europe include cerebrovascular disorders, age-related cognitive decline, and tinnitus. In the US, the compound is sold as a dietary supplement with FDA reservations about that designation given its drug-like history. Used as a cerebrovascular nootropic and PDE1 inhibitor in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-305Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Cannabigerol (CBG)

Our opinion on this compoundEstablished, active research

39/100

Multi-target phytocannabinoid with a distinct profile from CBD, but thin human evidence keeps it from standing out

Look, CBG occupies an interesting middle tier in cannabinoid research. It’s not CBD, it’s not THC, and that’s actually the point. The biosynthetic precursor role is mostly a curiosity at this stage, but the mechanistic profile is worth taking seriously. You’ve got weak CB1/CB2 partial agonism layered on top of alpha-2 adrenergic agonism, PPAR-gamma activity, and a 5-HT1A antagonism that runs opposite to what CBD does at the same receptor. That’s not a trivial distinction. It means CBG can serve as a controlled variable against CBD in serotonergic experiments, which gives it genuine probe utility that a lot of the cannabinoid space lacks.

What we like: the IBD preclinical work is solid enough to take seriously. Multiple labs have run colitis models and seen meaningful anti-inflammatory signal. The MRSA data from the Blaskovich group (2020) is among the more credible pieces of cannabinoid antibacterial work we’ve seen, though it hasn’t generated the follow-up it arguably deserves. Neuroprotection signals in Huntington and Parkinson models are interesting but still early, and it’s hard to know how much of that is CB receptor-mediated vs PPAR-gamma crosstalk.

Here’s the thing though: the human data is basically not there yet. CBG is sold as a supplement and there are scattered small human studies, but nothing with the design quality to anchor a serious clinical claim. The compound’s low natural abundance in mature cannabis plants created a sourcing constraint that historically slowed research down, and the high-CBG cultivar push is relatively recent. We’re still in the phase where preclinical signals are accumulating faster than human replication can catch up.

Differentiation is a real challenge. CBG isnt uniquely best-in-class for inflammation, neuroprotection, or any single indication. It’s one of a crowd, and compared to something like retatrutide or even MOTS-c, the mechanistic angle here isnt paradigm-shifting. The polypharmacology is real but it’s polypharmacology across targets that are individually saturated in the literature. Alpha-2 adrenergic has decades of work. PPAR-gamma is an extremely well-characterized nuclear receptor. The novelty comes from the combination and from the CBG-specific mechanistic fingerprint, not from any one target being new.

We think CBG is worth a position in a cannabinoid-focused research program, especially for labs doing CB receptor biology who want a low-intoxication tool with a distinct serotoninergic profile. But for a general-purpose research library, it sits firmly in the “watch and wait” tier until human replication data start arriving. The preclinical case is real; the translational case is still being built.

Novelty

42

Mechanism promise

45

In-category differentiation

40

Evidence quality

32

Translational signal

28

Research bench value

45

Rationale CBG scores moderate across the board: the polypharmacology profile (CB1/CB2 partial agonism, alpha-2 adrenergic, 5-HT1A antagonism, PPAR-gamma) is legitimately distinct from CBD and THC and earns mechanism credit, but the individual targets are all well-trodden, preclinical evidence is multi-lab but human data remains sparse, and the compound hasn’t yet produced a signal strong enough to distinguish it from the broader cannabinoid research cluster.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Phytocannabinoid (CB receptor weak agonist)

A non-intoxicating phytocannabinoid; the metabolic precursor of THC and CBD; investigated for inflammation, neuroprotection, and inflammatory bowel disease.

Abstract

Cannabigerol (CBG; CAS 25654-31-3; molecular formula C21H32O2; molecular weight 316.48) is a non-intoxicating phytocannabinoid from Cannabis sativa. The compound is the biosynthetic precursor of THC, CBD, and CBC in plants; mature plants typically contain less than 1 percent CBG owing to enzymatic conversion to these downstream cannabinoids. Mechanism: CB1 and CB2 partial agonism (weaker than THC), alpha-2 adrenergic agonism, 5-HT1A antagonism (opposite of CBD), and PPAR-gamma agonism. The mechanism profile is distinct from both THC and CBD. Preclinical evidence supports anti-inflammatory effects in colitis models, neuroprotection in Huntington and Parkinson models, and antibiotic activity against MRSA. Human clinical trial data are sparse; the compound is sold as a supplement with limited regulatory guidance. Plasma pharmacokinetics are similar to other phytocannabinoids: high lipophilicity, hepatic metabolism via CYP enzymes, long terminal half-life. Used as a non-intoxicating phytocannabinoid in inflammation and neuroprotection research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-321Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Harmaline

Plain-language summaryIntrigue 60 / 100

Harmaline is one of the three main beta-carboline alkaloids in the ayahuasca vine (Banisteriopsis caapi) and Syrian rue (Peganum harmala). Its critical pharmacological role is reversible MAO-A inhibition, which is what allows oral DMT to reach the brain in ayahuasca brews (without an MAO-A inhibitor, gut MAO destroys oral DMT before it can act centrally). Harmaline by itself produces vivid closed-eye visual imagery at high doses but is not a classical psychedelic. The reversible MAO inhibition is safer than the irreversible MAO inhibitors used as antidepressants but still creates real food and drug interaction risks. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

34/100

A reference MAO-A inhibitor and tremor-model tool with limited novelty and thin standalone clinical signal

Harmaline is one of those compounds that earns its place in a research library not because it’s novel or therapeutically exciting, but because it does a specific job that’s hard to replicate. The beta-carboline skeleton, shared with harmine and tetrahydroharmine, has been pulling double duty in ethnobotanical and neuropharmacology research for decades, and harmaline’s particular profile, reversible MAO-A inhibition with good selectivity over MAO-B (Ki around 5 µM at human MAO-A, over 100-fold selectivity), makes it a reference compound worth having around.

The MAO-A story is the center of gravity here. As one of the primary harmala alkaloids in ayahuasca preparations, harmaline’s pharmacological role is well understood: it inhibits intestinal and hepatic MAO-A, which would otherwise degrade DMT before systemic absorption. That’s genuinely important for understanding the brew’s oral bioavailability, but it also means harmaline’s most studied context is inseparable from a multi-compound mixture. Isolating its specific contributions to human pharmacology in that context is messy, and standalone human data on harmaline is thin.

What we find more interesting from a bench standpoint is the tremor model. Harmaline-induced tremor in rodents is one of the few pharmacologically validated animal models of essential tremor, and it’s been used across dozens of labs to probe the cerebello-olivary system, test tremor-suppressing drug candidates, and understand the oscillatory physiology underlying the condition. For labs working on motor control or essential tremor biology, harmaline isnt a curiosity, it’s infrastructure.

Outside the tremor work, the compound has some utility as a broader beta-carboline pharmacology probe. The class hits multiple targets at varying concentrations, including sigma receptors and some NMDA interactions at higher doses, and harmaline lets you explore that pharmacology with a reversible agent that clears reasonably fast (plasma half-life roughly 2 to 3 hours). That’s useful for experimental designs where you need to avoid prolonged MAO-A suppression and want a cleaner washout window than irreversible inhibitors allow.

What limits the score is that the mechanism landscape is mature. Reversible MAO-A inhibition as a pharmacological concept is not new ground; moclobemide covers the clinical story more cleanly, harmine covers much of the same structural territory with arguably more CNS penetration literature, and the therapeutic promise of harmaline specifically is low. The translational signal outside of ayahuasca context is weak. We think this one belongs in the library as a reference and model compound, not as a frontier research target. The score reflects that honestly.

Novelty

20

Mechanism promise

35

In-category differentiation

32

Evidence quality

45

Translational signal

25

Research bench value

62

Rationale Harmaline’s score is driven by its genuine but narrow bench utility: the harmaline-induced tremor model is a pharmacologically validated rodent model of essential tremor used across many labs, and its rMAO-A selectivity profile (Ki ~5 µM, >100-fold over MAO-B) makes it a useful reference compound. Novelty, mechanism, differentiation, and translational scores are low because the pharmacology is mature, the clinical picture outside the ayahuasca context is thin, and better alternatives exist for most of what it does.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Beta-carboline reversible MAO-A inhibitor

A beta-carboline alkaloid from Peganum harmala and Banisteriopsis caapi; a reversible MAO-A inhibitor and component of ayahuasca.

Abstract

Harmaline (4,9-dihydro-7-methoxy-1-methyl-3H-pyrido[3,4-b]indole; CAS 304-21-2; molecular formula C13H14N2O; molecular weight 214.27) is a beta-carboline alkaloid isolated from Peganum harmala (Syrian rue) and Banisteriopsis caapi (ayahuasca vine). The compound is a reversible MAO-A inhibitor (Ki approximately 5 microM at human MAO-A) with greater than 100-fold selectivity over MAO-B; this reversible MAO-A inhibition is central to the pharmacology of ayahuasca, where harmaline (and harmine) prevent intestinal breakdown of the DMT in the brew, allowing oral activity. Harmaline itself has serotonergic and tremorgenic effects in animals and mild psychoactive effects in humans. Plasma half-life is approximately 2 to 3 hours. Used as a reference reversible MAO-A inhibitor and as a research probe for beta-carboline pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-337Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Cyproheptadine

Plain-language summaryIntrigue 56 / 100

Cyproheptadine, sold as Periactin, is a first-generation antihistamine that also potently blocks 5-HT2A and 5-HT2C serotonin receptors. The combination gives it three fairly distinct clinical roles: appetite stimulation (5-HT2C blockade) used in pediatric failure-to-thrive and in cachexia; treatment of serotonin syndrome (5-HT2A blockade rapidly reverses the toxidrome); and migraine prophylaxis. The H1 and anticholinergic activity produces sedation and dry mouth as expected for a first-generation antihistamine. The serotonin syndrome reversal use is the most clinically important and is not interchangeable with other antihistamines. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

45/100

Old approved antihistamine with genuine 5-HT2 probe value and sole antidote status in serotonin syndrome

Cyproheptadine has been around since 1961. That fact alone shapes how you evaluate it as a research compound. The mechanism, the clinical uses, the pharmacology — all of it is mapped. There’s no meaningful “is this real” question left to ask.

What keeps it relevant is a narrow but genuinely useful set of properties. The dual H1 and 5-HT2A/5-HT2C antagonism profile isn’t something you replicate cleanly with newer, more selective agents. If you need to study the serotonin syndrome reversal mechanism or the appetite-stimulation pathway driven by 5-HT2C blockade, cyproheptadine is the canonical tool. It’s what investigators reach for when they want the combined H1/5-HT2 blockade signal in a single compound. That’s probe value: real, but narrow.

The serotonin syndrome angle is probably the most clinically interesting thing happening with this compound right now. It remains the only compound with a specific pharmacological rationale as an antidote, and as SSRI/SNRI prescriptions have climbed and combinations with triptans, tramadol, and other serotonergic agents become more common, there’s renewed interest in the reversal mechanism. Honest assessment: most of this is clinical pharmacology, not bench discovery. The compound isnt opening new mechanistic territory. Its confirming what we already know.

The post-SSRI sexual dysfunction research angle is newer and more interesting from a bench perspective. 5-HT2A antagonism is one of the proposed interventions for PSSD, and cyproheptadine gets cited in those discussions. But the evidence there is anecdotal-to-preliminary, and more selective 5-HT2A tools like ketanserin or volinanserin exist for investigators who want clean signal without the H1 confound.

What we think: cyproheptadine earns a place in a research library because of what it is, not what it’s becoming. Its differentiation in the serotonin syndrome space is real. Its evidence quality and translational signal are solid by virtue of six decades of clinical use. But its novelty is essentially zero, and the bench-scale questions it can answer are mostly answered. A serious investigator building a new research program in 2025 would reach for this to confirm a mechanism or use it as a comparator, not as the focus of a program.

We stock it because it’s the reference 5-HT2 antagonist antihistamine with an irreplaceable clinical niche. Thats a legitimate reason. Its just not a reason to call it exciting.

Novelty

20

Mechanism promise

38

In-category differentiation

50

Evidence quality

60

Translational signal

65

Research bench value

50

Rationale Novelty is near-floor for a 1961 approved compound with fully mapped pharmacology, but differentiation and bench value score meaningfully higher because the combined H1/5-HT2A/5-HT2C profile is genuinely unique and its role as the only pharmacological serotonin syndrome antidote is uncontested; strong translational and evidence scores reflect 60-plus years of clinical use, not discovery-stage excitement.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

First-generation antihistamine + 5-HT2 antagonist

A piperidine first-generation antihistamine with 5-HT2A and 5-HT2C antagonist activity; used for appetite stimulation, serotonin syndrome reversal, and migraine prophylaxis.

Abstract

Cyproheptadine (4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine; CAS 129-03-3; molecular formula C21H21N; molecular weight 287.40) is a piperidine first-generation antihistamine with potent 5-HT2A and 5-HT2C antagonist activity, approved by the FDA in 1961 (Periactin). The compound combines H1 antihistamine activity (Ki approximately 1 nM, comparable to diphenhydramine) with strong 5-HT2 antagonism (Ki approximately 1 nM at 5-HT2A); the combined activity drives appetite stimulation (5-HT2C antagonism, the same mechanism as the appetite gain seen with olanzapine and clozapine), serotonin syndrome reversal, and migraine prophylaxis. Plasma half-life is approximately 8 hours. Approved for allergic conditions; off-label use in failure-to-thrive (pediatric appetite stimulation), serotonin syndrome (the only specific antidote besides supportive care), and post-SSRI sexual dysfunction (5-HT2A antagonism). Used as the canonical 5-HT2 antagonist antihistamine in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-353Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Testosterone (Research)

Plain-language summaryIntrigue 75 / 100

Testosterone is the principal androgen in humans, made from cholesterol in the testes (men) and ovaries plus adrenals (women). It is the foundational compound of androgen pharmacology and the active ingredient in essentially all testosterone replacement therapy plus the backbone of most non-medical anabolic steroid stacks. It binds the androgen receptor directly and is also converted on the fly into dihydrotestosterone (more potent androgen) by 5-alpha-reductase, and into estradiol by aromatase. Sold as cypionate, enanthate, propionate, undecanoate, plus gels and patches, with each ester releasing testosterone over different timescales. Schedule III in the US. The reference androgen receptor agonist for nearly all related research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

44/100

Canonical AR reference compound; foundational but thoroughly mapped, with frontier interest squarely elsewhere

Look, testosterone occupies a genuinely strange position in any research library. It’s the foundational androgen – first isolated by David, Dingemanse, Freud, and Laqueur in 1935, structure confirmed by Butenandt and Ruzicka (Nobel, 1939), and under continuous clinical deployment ever since. At this point, the AR pharmacology is about as well-characterized as receptor biology gets. Ki of roughly 0.5 nM at AR, 5-alpha-reductase conversion to the more potent DHT, aromatase conversion to estradiol. We know this chemistry cold. Thats not a criticism; its just the reality of a compound that has been under rigorous investigation for ninety years across thousands of labs.

The mechanism doesn’t earn novelty points here. Single-receptor agonism in the most saturated steroid class in pharmacology. The interesting research questions around androgen biology, tissue selectivity, AR coactivator recruitment, non-genomic signaling pathways: those are now answered more cleanly with SARMs and selective AR modulators designed specifically to probe those dimensions. If you want to study differential anabolic-to-androgenic ratios, LGD-4033 or RAD-140 are sharper instruments. If you want AR pathway studies without aromatization confound, you need to block aromatase anyway. Testosterone does AR agonism and aromatization simultaneously, which is a physiological feature but a research design confounder.

What actually scores well here is evidence quality and translational signal, and those scores are real. FDA approval for hypogonadism across multiple ester formulations (cypionate, enanthate, propionate, undecanoate). Decades of replicated RCTs, well-characterized PK across routes of administration, solid safety profiling across hematocrit, lipid, and hormonal endpoints. If you’re building a disease model around male hypogonadism or studying androgen-mediated muscle protein synthesis in a clinical context, this is your reference compound, full stop.

Where we find genuine bench value is specifically in the reference probe role. AR binding competition assays, androgen-responsive cell line studies (LNCaP, LAPC4), steroidogenesis pathway models, castration-and-replacement designs in rodents: testosterone is the canonical standard against which everything else is calibrated. That role keeps the bench value score from collapsing. But it’s not a compound you reach for because you’re curious about what it does. You reach for it because you need to establish what something else does relative to it.

Honestly, the overall score here reflects one simple fact: testosterone is so thoroughly understood that the primary research questions it can answer are mostly already answered. The frontier in androgen biology has moved to selective modulators, non-steroidal AR ligands, the androgen receptor splice variants driving castration-resistant prostate cancer, and the complex crosstalk between androgen signaling and metabolic pathways. Testosterone stays in the library as a reference standard and clinical backbone. As an object of primary investigation in 2026, its not where serious investigators are finding new ground.

Novelty

10

Mechanism promise

20

In-category differentiation

42

Evidence quality

80

Translational signal

74

Research bench value

68

Rationale Testosterone scores high on evidence quality and translational signal (FDA-approved, multi-decade RCT base) but bottoms out on novelty and mechanism promise; it’s the prototype AR agonist in the most saturated steroid pharmacology class in existence, and the live research questions in androgen biology are now prosecuted more precisely with SARMs and selective probes. The Schedule III cap (75) does not bind because the weighted score lands well below it.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous androgen / anabolic-androgenic steroid

The principal endogenous androgen; the foundational compound of androgen pharmacology and the active component of TRT and many AAS regimens.

Abstract

Testosterone (17-beta-hydroxyandrost-4-en-3-one; CAS 58-22-0; molecular formula C19H28O2; molecular weight 288.42) is the principal endogenous androgen, biosynthesized from cholesterol via pregnenolone and progesterone in Leydig cells of the testis (males) and theca cells, ovary, and adrenal cortex (females). The compound is the prototype androgen receptor agonist and the foundation of androgen pharmacology. Pharmacologically, testosterone binds AR (Ki approximately 0.5 nM) and is converted to dihydrotestosterone (DHT) by 5-alpha-reductase (more potent AR agonist) and to estradiol by aromatase (estrogen receptor agonist). Approved as testosterone replacement therapy in male hypogonadism via various ester formulations: cypionate (weekly), enanthate (weekly), propionate (every 2 to 3 days), undecanoate (oral and depot), gels and patches (daily). Schedule III in the US under the CSA. The compound is the foundation of most anabolic-androgenic steroid (AAS) regimens used non-medically for muscle building. Plasma half-life of native testosterone is short (1 to 2 hours); ester formulations release the parent compound over days. Used as the canonical AR agonist in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-386Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Sermorelin

Plain-language summaryIntrigue 60 / 100

Sermorelin is the first 29 amino acids of growth hormone releasing hormone (the active portion). It triggers natural pulsatile growth hormone release from the pituitary. Approved historically for pediatric growth hormone deficiency before being discontinued in 2008. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

38/100

Historically important GHRH fragment now superseded by longer-acting analogs with better pharmacokinetics

Sermorelin is the granddaddy of the GHRH peptide class. The 29-amino-acid N-terminal fragment of human GHRH, it retains full GHRHR agonist activity and was FDA-approved under the trade name Geref for pediatric GH deficiency before the brand was discontinued in 2008 for commercial reasons, not safety or efficacy ones. The mechanism is about as well-defined as it gets: GHRHR activation at the anterior pituitary, triggering pulsatile GH secretion. That signal has been observed and replicated in humans across multiple clinical programs, which is about the nicest thing we can say about the evidence base here.

Here’s the thing though: sermorelin is, by almost every research metric, the weakest member of the GHRH analog family available today. Its plasma half-life runs 11 to 12 minutes subcutaneously. CJC-1295 without DAC gives you a comparable pharmacological profile with a meaningfully longer active window; CJC-1295 with the drug affinity complex stretches GH stimulation across days by binding to albumin. Tesamorelin, the full GHRH(1-44) fragment stabilized for pharmaceutical use, earned FDA approval for HIV-associated lipodystrophy and carries a cleaner modern regulatory track record. Any of these outcompete sermorelin on pharmacokinetics or clinical validation, often both. For most research programs focused on the GH axis, sermorelin isnt the default choice anymore and hasnt been for some time.

The combination data with GHRPs is the most defensible current angle. Synergistic GH release when sermorelin is co-administered with ipamorelin or GHRP-2 has been documented and is mechanistically sensible: you’re hitting both GHRHR and the ghrelin receptor simultaneously, producing a larger and more sustained GH pulse than either agent alone. Some labs and compounding setups favor sermorelin specifically because of this established synergy literature. We think that’s a reasonable use case, but the same synergy is achievable with CJC-1295 and superior pharmacokinetics to boot.

Evidence quality is genuinely the bright spot. Multiple replicated clinical trials, a real regulatory history, and decades of preclinical mechanistic work give sermorelin a credibility that compounds like Epitalon or TB-500 will never match. The translational signal for GH deficiency is unambiguous. But research-merit scoring isnt about how much we trust something works for its approved indication; it’s about whether this is a compelling target right now. On that question, sermorelin lands squarely in established-mature territory: historically important, still serviceable as a GHRHR probe for acute GH axis work, but not where the interesting mechanistic questions are being asked in 2025 and 2026. The field has produced better tools for the same job.

Novelty

22

Mechanism promise

35

In-category differentiation

22

Evidence quality

62

Translational signal

60

Research bench value

38

Rationale Sermorelin’s FDA history (Geref, pediatric GH deficiency) and replicated clinical evidence are genuine assets, but the 11-12 minute plasma half-life and wide availability of CJC-1295 variants leave it in the superseded tier of GHRH analogs; low novelty and differentiation scores drag the overall into the established-mature range.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GHRH 1-29 analog

A 29-amino-acid synthetic fragment of GHRH (residues 1-29) used for growth hormone deficiency diagnosis and treatment.

Abstract

Sermorelin (GRF 1-29; CAS 86168-78-7; molecular weight 3357.93) is a synthetic peptide consisting of the first 29 amino acids of human growth hormone releasing hormone (GHRH). The 1-29 fragment retains essentially all the GH-stimulating activity of full-length GHRH (44 residues) and was the basis for the FDA approval (under the trade name Geref) for GH deficiency in children. The brand-name product was discontinued in 2008 for commercial reasons; sermorelin is now compounded for clinical use in some jurisdictions and sold as a research chemical. The compound is administered subcutaneously and stimulates pituitary GH release through GHRH receptor activation, distinct from the ghrelin receptor agonism of GHRPs. Combination of sermorelin with a GHRP (ipamorelin, GHRP-2) produces synergistic GH release. Pharmacokinetics: plasma half-life 11 to 12 minutes; subcutaneous bioavailability good. Doses for GH deficiency are 0.3 mcg/kg subcutaneously once daily at bedtime.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-079Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 55 56 57 58 59 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.